The effectiveness of cilofungin (LY121019, referred to hereafter as LY), a lipopeptide, was studied in a murine candidiasis model. CD-1 mice (5 weeks old) were injected intravenously with 3 x 1j9 Candida albicans yeast cels. Intraperitoneal LY or amphotericin B (AmB) therapy was begun 4 days after infection and was continued daily for 2 weeks. LY and AmB were compared at 62.5, 6.25, and 0.625 mg/kg per day, with the LY dose split into two treatments per day. Mice were observed for 30 days postinfection, and survivors were necropsied. AmB at 62.5 mg/kg per day was lethal in the absence of infection. Cumulative mortality for infected controls was 94% (17 of 18). Survival of mice treated with the control diluent for LY was the same as survival with no treatment. Survival after 0.625 mg of LY per kg per day was the same as that of the controls, and 6.25 or 62.5 mg of LY per kg per day was significantly superior. AmB treatment at 0.625 or 6.25 mg/kg per day was protective and superior to the same LY doses. Atrophied kidneys were common in AmB-treated mice, and mice treated with 6.25 mg of AmB per kg per day appeared iUl during therapy. The number of CFU recovered from kidneys and spleens of surviving mice reflected the same relationships between drugs and doses as those described for mortality. C. albicans was not cleared from the kidneys of mice in any group, and only in the 6.25-mg/kg-per-day AmB treatment group was no detectable C. albicans found in the spleens. These data indicate that LY or AmB suppresses candida infection but neither is curative in this model. Cilofungin (LY121019, referred to hereafter as LY) is a semisynthetic antibiotic with potent anticandidal activity in vitro (7, 8, 12) . A novel lipopeptide analog of echinocandin B, LY belongs to a new chemical class of polypeptide antifungal agents which have been reported to inhibit the incorporation of ,-1,3-glucan into the fungal cell wall (1, 2, 10). Scanning electron microscopic studies have shown that Candida albicans grown in the presence of LY develops severely damaged cell walls (5). The MICs for 50 and 90%o of strains tested (MIC50 and MIC90) of LY were identical to those of amphotericin B (AmB) against 96 isolates of C. albicans (5). LY has potent fungicidal activity against Candida spp. in vitro. Other pathogenic fungi tested are much less susceptible to LY (7, 8) . Given the narrow spectrum of LY in vitro and its low toxicity in vivo (LY was shown to have no more than 1/20 the toxicity of AmB in dogs [5]), we compared the effects of LY therapy to those of AmB on intravenously induced murine candidiasis.
Cilofungin (LY121019, referred to hereafter as LY) is a semisynthetic antibiotic with potent anticandidal activity in vitro (7, 8, 12) . A novel lipopeptide analog of echinocandin B, LY belongs to a new chemical class of polypeptide antifungal agents which have been reported to inhibit the incorporation of ,-1,3-glucan into the fungal cell wall (1, 2, 10) . Scanning electron microscopic studies have shown that Candida albicans grown in the presence of LY develops severely damaged cell walls (5) . The MICs for 50 and 90%o of strains tested (MIC50 and MIC90) of LY were identical to those of amphotericin B (AmB) against 96 isolates of C. albicans (5) . LY has potent fungicidal activity against Candida spp. in vitro. Other pathogenic fungi tested are much less susceptible to LY (7, 8) . Given the narrow spectrum of LY in vitro and its low toxicity in vivo (LY was shown to have no more than 1/20 the toxicity of AmB in dogs [5] ), we compared the effects of LY therapy to those of AmB on intravenously induced murine candidiasis.
MATERIALS AND METHODS C. albicans. The fungal isolate used in this study (C. albicans 5) was susceptible in vitro to LY (MIC, 0.625 ,ug/ml) and AmB (MIC, 0.5 j,g/ml), as determined by previously described methods (4) . Yeast nitrogen base broth (Difco Laboratories, Detroit, Mich.) with 0.5% glucose was inoculated with growth from Sabouraud agar slants. Yeast cells were grown overnight at 35°C without agitation, washed three times in sterile 0.85% saline, and serially diluted in saline.
Inoculation of mice. Five-week-old specific-pathogen-free male CD-1 mice (Charles River Breeding Laboratories, Inc., * Corresponding author. Portage, Mich.) were used in a model of systemic candidiasis described previously (9, 14) .
Groups of 10 to 18 mice (average weight, 30 g) were infected via injection of 0.2 ml of C. albicans suspension into the lateral tail vein (3 x also had a sterile spleen, as described below). The clearance in all treatment groups except the 0.625-mg/kg-per-day LY group was significantly superior to that in controls (untreated plus PEG 300 diluent treated) (P < 0.001). The higher AmB dose regimen was significantly superior to each LY regimen in terms of clearance, and the lower AmB regimen was significantly superior to the lower two LY regimens (0.625 and 6.25 mg/kg per day) (P < 0.001 for all comparisons). The higher AmB dose was superior to the lower AmB dose (P < 0.01), and the lower LY regimen was significantly inferior to the two higher LY regimens (P < 0.001).
All untreated control, PEG 300-treated, and LY-treated (0.625 and 6.25 mg/kg per day) mice had residual splenic fungal disease after specimens were taken from them for culture (Fig. 2) (5) , in which CFU from kidneys were reduced by 2 logs, relative to our own study, in which LY treatment resulted in a reduction of CFU from kidneys by 1 log. These differences may be due to the delay before initiation of treatment in our system or to the different route of infection employed (intraperitoneal versus intravenous).
The antifungal effects of LY have been ascribed to its inhibition of fungal cell wall P-1,3-glucan biosynthesis (5).
Since this mode of action is different from that of the conventional antifungal drugs such as AmB, which binds to membrane sterols causing leakage (6, 11), or the azoles, which inhibit sterol synthesis and have other actions (3, 12, 16) , it would be of interest to determine whether synergistic therapies could be developed between LY and other antifungal agents. Alternatively, the administration of LY concentrations slightly higher than those tested in our study (greater than 62.5 mg/kg per day) would be of interest to examine, since significant toxicity (hepatotoxicity) does not appear to occur until doses of 100 mg/kg are administered (5) . Synergistic drug regimens may prove to be the most effective, however, since LY requires active metabolism by candidal cells for antifungal effectiveness (5) while AmB or the azoles are also effective against nonmetabolizing fungi (6, 11, 16) . We conclude that LY may prove to be of therapeutic value alone or in combination with other antifungal agents in the treatment of systemic candidal infection; however, while LY and AmB were effective in suppressing candidal infection, neither drug alone was curative in our model.
